Show simple item record

dc.contributor.authorJoshi, MD
dc.contributor.authorUnger, WJ
dc.contributor.authorStorm, G
dc.contributor.authorvan Kooyk, Y
dc.contributor.authorMastrobattista, E
dc.date.accessioned2013-07-30T13:24:17Z
dc.date.available2013-07-30T13:24:17Z
dc.date.issued2012
dc.identifier.citationJ Control Release. 2012 Jul 10;161(1):25-37. doi: 10.1016/j.jconrel.2012.05.010. Epub 2012 May 10.en
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/22580109
dc.identifier.urihttp://hdl.handle.net/11295/52650
dc.description.abstractDendritic cells play a central role in antigen presentation and generation of cytotoxic T lymphocyte (CTL) response required for anticancer vaccination. The review focuses on use of particulate carriers like lipid and polymeric nanoparticles for targeting tumor antigens to the dendritic cells. The role of various physicochemical parameters of nanocarriers such as size, surface charge in passive targeting is detailed. Utilization of different ligands such as mannose, Fc receptor, CD11c/CD 18, DEC-205 and DC-SIGN on DC for active targeting is reviewed. Smart nanocarriers such as pH sensitive nanocarriers, pre forming liposomes, cell penetrating peptide containing systems and virosomes that can specifically increase the CTL response generating greater antitumor immunity have also been discussed.en
dc.language.isoenen
dc.publisherUniversity of Nairobien
dc.titleTargeting tumor antigens to dendritic cells using particulate carriers.en
dc.typeArticleen
local.publisherFaculty of medicineen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record